Raycaster

Executive Summary

Raycaster is an early-stage AI/ML company at the intersection of deep learning and structural biology, focusing on predicting protein-ligand interactions and protein folding to accelerate drug discovery. Founded in 2024 and based in the USA, the company has developed a computational platform that enables rapid identification and optimization of novel drug candidates, aiming to significantly enhance R&D productivity for biopharma partners. Although still in the platform stage with fewer than 50 employees, Raycaster's approach applies state-of-the-art deep learning models to a critical bottleneck in drug development. The company's inclusion in Y Combinator's biotech cohort signals strong potential, and its partnerships with biopharma firms provide early validation. If successful, Raycaster could become a key enabler in the drug discovery pipeline, reducing time and cost for bringing new therapies to market. The main risks are typical for deep-tech startups: technical validation, competitive landscape (e.g., DeepMind, Schrödinger), and commercial traction.

Upcoming Catalysts (preview)

• TBDPartnership announcement with top-20 pharma company40% success
• TBDPublication of benchmark results on protein-ligand interaction prediction50% success
• TBDSeries A funding round led by prominent life sciences VC35% success